Abstract：Objective：To observe the clinical effect of Bufei Yishen Pingchuan tang combined with salmeterol rotticasone for chronic obstructive pulmonary disease(COPD) at stable stage. Methods：A total of 78 cases of COPD patients at stable stage were selected and divided into the control group and the observation group，with 39 cases in each group. The control group was given salmeterol rotticasone inhalation， and the observation group was additionally treated with Bufei Yishen Pingchuan tang based on the treatment of the control group. Both groups were treated for 12 weeks. Clinical effects were compared between the two groups. The lung function indexes including forced expiratory volume in one second(FEV1)，forced vital capacity(FVC)，and the ratio of FEV1 to FVC before and after treatment were detected. Changes in scores of Modified Medical Research Council(mMRC) and COPD Assessment Test(CAT) were compared between the two groups. Results：The total effective rate was 94.87% in the observation group， higher than that of 79.49% in the control group， the difference being significant(P＜0.05). Before treatment，there was no significant difference being found in the comparison of FEV1，FVC and FEV1/FVC between the two groups(P＞0.05). After treatment， FEV1， FVC and FEV1/FVC in the two groups were increased when compared with those before treatment， and the three indexes in the observation group were higher than those in the control group，the difference being significant(P＜0.05). Before treatment，there was no significant difference being found in the comparison of scores of mMRC and CAT between the two groups(P＞0.05). After treatment，scores of mMRC and CAT in the two groups were decreased when compared with those before treatment，and the scores of mMRC and CAT in the observation group were lower than those in the control group(P＜0.05). Conclusion：Bufei Yishen Pingchuan tang combined with salmeterol rotticasone has a defined curative effect in the treatment of COPD patients at stable stage， and it can more effectively improve clinical symptoms and the lung function.